AQST News and Press, Aquestive Therapeutics Inc. From 09/28/20

Gainers: Genfit (GNFT) +35%, Trxade Group (MEDS) +20%, Celldex Therapeutics (CLDX) +15%, EDAP TMS (EDAP) +13%, Kaleido Biosciences (KLDO) +8%.Losers: Abeona Therapeutics (ABEO) -33%, Aquestive Therapeutics (AQST) -35%, Mallinckrodt (MNK)&...

Aquestive Therapeutics (AQST) announces that FDA has issued a complete response letter regarding the New Drug Application  for Libervant Buccal Film for management of seizure clusters.FDA cited that, in a study submitted by the company with the NDA, certain weight groups showed a lo...

Complete Response Letter cites exposure levels (Cmax) in certain weight groups No additional clinical studies anticipated by Aquestive No Clinical Safety issues or Non-Clinical Chemistry, Manufacturing and Controls (CMC) issues identified Conference call and webcast today at 6...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Aquestive Therapeutics (NASDAQ: AQST ) initiates a Phase 1 clinical trial in 28 healthy volunteers evaluating the safety and pharmacokinetics (PK) of AQST-108, an oral sublingual formulation of epinephrine, for the potential treatment of allergic reactions, including anaphylaxis (ac...

First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxis Pharmacokinetic and pharmacodynamics data expected in fourth quarter 2020 WARREN, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQ...

Overview Aquestive Therapeutics (NASDAQ: AQST ) has posted Q2 results beating the street by $0.36 in EPS and $12.91 million in revenues, on the back of a sturdy quarter related to sales of its licensed commercialised pharmaceutical products, including Sympazan, Suboxone, Kynmobi and Zuplenz....

Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108 First planned PK clinical trial expected to begin during the third quarter of 2020 WARREN, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused...

Image source: The Motley Fool. Aquestive Therapeutics, Inc.   (NASDAQ: AQST) Q2 2020 Earnings Call Aug 05, 2020 , 8:00 a.m. ET Operator Continue reading

For  Q2 , Aquestive Therapeutics ( AQST +6.2% ) revenues of $21.7M vs. $11.1M; indicating increased licensing fees and royalty revenue ($12M for KYNMOBI approval). More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,...